Subtype
Digestive System Carcinoma
CI-CAN-00000812Explore in graph →
2,123 active trials27 approved drugs139 evidence items
- NCIt
- C96963
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000812Explore in graph →
Clinical trials
7,540 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (884)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06475196 | Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable ESCC | unknown | — | 90 | Tang-Du HospitalOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06475287 | HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 42 | Fudan UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT05444088 | Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 129 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06467565 | NALIRIFOX as Induction Therapy in LAPC | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06458725 | Assessment of DW-MRI Measures : Reproducibility and Repeatability in Pelvic Imaging on MR-Linac With Healthy Volunteers(PILLAR) | unknown | N/A | 30 | Jules Bordet InstituteOTHER | 0 | Jun 14, 2024 | clinicaltrials |
| NCT05717738 | Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma(CCGLC-008) | unknown | — | 300 | Tongji HospitalOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT05304234 | Liver Cancer Disparities in American Indian and Alaska Native Persons | unknown | Phase 2 | 200 | University of WashingtonOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06434753 | Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease. | unknown | Phase 3 | 300 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT03356236 | Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation | unknown | — | 828 | Yue HanOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT06429865 | Cytosponge in Surveillance After Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma | unknown | N/A | 1,000 | Changhai HospitalOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT06417606 | Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma | unknown | Phase 4 | 20 | Zhiyong HuangOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT03992456 | Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer | unknown | Phase 2 | 12 | Academic and Community Cancer Research UnitedOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT05490719 | A Phase II Study of CRT Combined With QL1706 in ESCC Patients | unknown | Phase 2 | 39 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT06423144 | PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7 | unknown | — | 150 | Shanghai Zhongshan HospitalOTHER | 0 | May 21, 2024 | clinicaltrials |
| NCT03337087 | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | unknown | Phase 1 / Phase 2 | 18 | Academic and Community Cancer Research UnitedOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT06261008 | Interactive Telehealth Intervention to Increase Longitudinal Adherence to Repeat Faecal Immunochemical Test Screening | unknown | N/A | 370 | Chinese University of Hong KongOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT06036563 | Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing | unknown | — | 3,200 | Air Force Military Medical University, ChinaOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06410677 | Changhai Multimodal Esophageal Cancer Cohort(CMECC) | unknown | — | 110 | WangluoweiOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT04159974 | RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus(RICE) | unknown | Phase 2 | 56 | University of CologneOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT04755920 | SGM-101 in Colorectal Brain Metastases.(SGM-CBM) | unknown | Phase 2 | 10 | Leiden University Medical CenterOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT02509286 | Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus(ESOPEC) | unknown | Phase 3 | 438 | University Hospital Schleswig-HolsteinOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06396143 | Research on Intelligent Screening and Decision-making for Neoadjuvant Therapy in Locally Advanced Gastric Cancer Based on Multi-omics Integration | unknown | — | 120 | Zhejiang UniversityOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06206096 | PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC | unknown | Phase 2 | 40 | Chinese PLA General HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06272656 | Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular Carcinoma | unknown | — | 200 | Hebei Medical University Third HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06252974 | Accurate Diagnosis of the Invasion Depth in ESCC by a Deep Neural Network Analysis of NBI Endoscopy Data | unknown | — | 500 | RenJi HospitalOTHER | 0 | Apr 29, 2024 | clinicaltrials |
| NCT06212700 | PRIORITY-CONNECT 2 Pilot Trial | unknown | N/A | 20 | Surgical Outcomes Research Centre (SOuRCe)NETWORK | 1 | Apr 25, 2024 | clinicaltrials |
| NCT06384950 | Evaluating the Role of ChatGPT in Educating Patients With Early-stage Hepatocellular Carcinoma | unknown | N/A | 450 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Apr 25, 2024 | clinicaltrials |
| NCT04143152 | Pancreatic Cancer Biomarker Study | unknown | — | 300 | Van Andel Research InstituteOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT04301557 | PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer | unknown | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06375486 | Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）. | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06375642 | A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT03732105 | Randomized Study of Adjuvant Radiotherapy After Curative Resection of HCC With Narrow Margin (RAISE)(RAISE) | unknown | N/A | 148 | Sun Yat-sen UniversityOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT04104230 | Quebec Pancreas Cancer Study(QPCS) | unknown | — | 2,000 | George ZogopoulosOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06369480 | Prognostic Factors for Survival in Patients With Cholangiocarcinoma | unknown | — | 2,000 | Rigshospitalet, DenmarkOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06370065 | Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients | unknown | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06363123 | Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis | unknown | — | 2,700 | Beijing Friendship HospitalOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT06365034 | Study on the Efficacy and Safety of Conversion Therapy in Patients With Initially Unresectable Hepatocellular Carcinoma | unknown | — | 92 | Qianfoshan HospitalOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT06061445 | Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma | unknown | N/A | 22 | Fujian Cancer HospitalOTHER_GOV | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06362070 | Comparison of Outcomes of Multiple Platforms for Assisted Robotic - Gastrectomy | unknown | N/A | 75 | Azienda Ospedaliera Universitaria Integrata VeronaOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06364007 | HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC | unknown | Phase 2 | 20 | Sulai LiuOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05519605 | Bile Duct Drainage After ERCP Failure: EUS-BD vs PTBD(BESTDRAIN) | unknown | — | 61 | Radboud University Medical CenterOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06355700 | Hepatocellular Carcinoma Liver Organoids(HELIO) | unknown | N/A | 10 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT05626985 | Refinement and Validation of a Diagnostic Model (GAMAD) for Early Detection of Hepatocellular Carcinoma | unknown | — | 2,000 | Singlera Genomics Inc.INDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06231680 | Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) | unknown | Phase 2 | 132 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 29, 2024 | clinicaltrials |
| NCT06335927 | HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC | unknown | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT05048524 | Peri-operative SLOG for Localized Pancreatic Cancer | unknown | Phase 2 | 64 | National Health Research Institutes, TaiwanOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT05170802 | Pancreatic Cancer & Surgical Resection | unknown | — | 30 | Methodist Health SystemOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06325267 | Clinical Characteristics of Primary Liver Cancer | unknown | — | 1,000 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 27, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jun 26, 2024source: clinicaltrials